It is feasible that Bcl-2 represses immunotherapy-induced apoptosis in RCC cells, as all primary tumours from responders to immunotherapy were negative for Bcl-2 in this study; however, a clinical response was observed in only eight of 27 (29.6%) Bcl-2-negative cases. This evidence concerns the gene BCL2 and renal cell carcinoma.